Compare · CLOV vs NTRA
CLOV vs NTRA
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $33.62B, about 12.6x CLOV ($2.67B).
- Over the past year, CLOV is up 77.8% and NTRA is up 36.6% - CLOV leads by 41.2 points.
- NTRA has been more active in the news (20 items in the past 4 weeks vs 9 for CLOV).
- NTRA has more recent analyst coverage (25 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Natera Inc.
- Price
- $5.05-1.37%
- $234.83+2.57%
- Market cap
- $2.67B
- $33.62B
- 1M return
- +40.28%
- +15.34%
- 1Y return
- +77.82%
- +36.58%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 9
- 20
- Recent ratings
- 12
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CLOV
- Clover Health Investments Corp. filed SEC Form 8-K: Other Events
- CEO, Medicare Advantage Reynoso Jamie L. sold $11,281 worth of shares (2,360 units at $4.78) as part of a pre-agreed trading plan, decreasing direct ownership by 0.08% to 2,841,211 units (SEC Form 4)
- VP OF FINANCE AND CONTROLLER Oldakowski Joseph Frank sold $58,816 worth of shares (12,102 units at $4.86), decreasing direct ownership by 4% to 299,067 units (SEC Form 4) (for tax liability)
- Clover Health Investments Corp. filed SEC Form 8-K: Leadership Update
- Chief Legal Officer Soares Karen sold $21,579 worth of shares (4,681 units at $4.61), decreasing direct ownership by 0.30% to 1,567,741 units (SEC Form 4) (withholding obligation)
- CEO, Medicare Advantage Reynoso Jamie L. sold $29,274 worth of shares (6,350 units at $4.61), decreasing direct ownership by 0.22% to 2,843,571 units (SEC Form 4) to satisfy withholding obligation
- Clover Health Investments Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CEO, Medicare Advantage Reynoso Jamie L. sold $35,789 worth of shares (7,289 units at $4.91) as part of a pre-agreed trading plan, decreasing direct ownership by 0.26% to 2,849,921 units (SEC Form 4)
- Clover Health Investments Corp. filed SEC Form 8-K: Other Events
- CEO, Counterpart Health Wai Conrad sold $879,500 worth of shares (220,426 units at $3.99) as part of a pre-agreed trading plan (SEC Form 4)
Latest NTRA
- NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
- CO-FOUNDER Sheena Jonathan sold $329,810 worth of shares (1,500 units at $219.87) as part of a pre-agreed trading plan (SEC Form 4)
- Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
- Director Chapman Rowan E sold $642,536 worth of shares (2,964 units at $216.78) as part of a pre-agreed trading plan, decreasing direct ownership by 49% to 3,124 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $665,087 worth of shares (3,150 units at $211.14) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 249,352 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $21,447,308 worth of shares (100,000 units at $214.47) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 2,277,843 units (SEC Form 4)
- Amendment: Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- RBC Capital Mkts resumed coverage on Natera with a new price target
- Director Marcus Gail Boxer sold $2,389,328 worth of shares (11,000 units at $217.21) and exercised 11,000 shares at a strike of $22.83 (SEC Form 4)